Search results
Results from the WOW.Com Content Network
The Food and Drug Administration began to review the safety of triclocarban and triclosan in the 1970s, but due to the difficulties of finding antimicrobial alternatives, no final policy, or "drug monograph," was established. [20] Legal action by the Natural Resources Defense Council in 2010 forced the FDA to review triclocarban and triclosan. [20]
The FDA stated "There is no data demonstrating that over-the-counter antibacterial soaps are better at preventing illness than washing with plain soap and water". [6] The agency also asserted that despite requests for such information, the FDA did not receive sufficient data from manufacturers on the long-term health effects of these chemicals.
Its efficacy as an antimicrobial agent, the risk of antimicrobial resistance, and its possible role in disrupted hormonal development remains controversial. Additional research seeks to understand its potential effects on organisms and environmental health. Triclosan was developed in 1966. [1]
The FDA also said that using unapproved animal drugs in humans could delay effective treatment and allow infections to become severe and resistant to antibiotics and anti-fungal drugs.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. [1] [2] They may either kill or inhibit the growth of bacteria.
The FDA announced a proposal to remove oral phenylephrine, found in many popular OTC decongestants, from shelves. The reason for the ban is that the ingredient just isn’t effective, the FDA says.
An antimicrobial is an agent that kills microorganisms (microbicide) or stops their growth (bacteriostatic agent). [1] Antimicrobial medicines can be grouped according to the microorganisms they act primarily against. For example, antibiotics are used against bacteria, and antifungals are used against fungi. They can also be classified ...
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.